Moderna Entered into a Research and Development Collaboration with Metagenomi to Develop In Vivo Gene Editing Therapeutics
Shots:
- Metagenomi to receive an up front, equity investment & is eligible to receive target option exercise fees in addition to development, regulatory, and commercial milestones along with royalties on net sales of any products
- The collaboration will combine Metagenomi’s CRISPR-based & other novel gene editing systems with Moderna’s mRNA and LNP technologies to advance the development of in vivo gene editing therapeutics for the treatment of patients with serious genetic diseases
- Additionally, both companies will advance a series of in vivo gene editing therapeutics against undisclosed targets while Moderna focuses is to developing mRNA-based medicines
Click here to read the full press release/ article | Ref: Businesswire | Image: Indian Express